PRCT (PROCEPT BioRobotics) Piotroski F-Score: 4 (As of Jun. 29, 2026) — 20% Below Median


PRCT PROCEPT BioRobotics Corp PRCT
70 GF Score
Price $22.65
GF Value $92.12
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is PROCEPT BioRobotics Piotroski F-Score?

PROCEPT BioRobotics PRCT +0.40% 70 Piotroski F-Score is 4 as of Jun. 29, 2026, which is 20% below its 10-year median of 5.00. GuruFocus rates PRCT with a GF Score™ of 70/100 and a GF Value™ of $92.12 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 806 Medical Devices & Instruments companies, PROCEPT BioRobotics ranks worse than 56.45% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

PROCEPT BioRobotics has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for PROCEPT BioRobotics's Piotroski F-Score or its related term are showing as below:

PRCT' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 5   Max: 6
Current: 4

During the past 7 years, the highest Piotroski F-Score of PROCEPT BioRobotics was 6. The lowest was 2. And the median was 5.

PROCEPT BioRobotics  (NAS:PRCT) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


PROCEPT BioRobotics Piotroski F-Score Related Terms


PROCEPT BioRobotics Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for PROCEPT BioRobotics's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PROCEPT BioRobotics Piotroski F-Score Chart

PROCEPT BioRobotics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial N/A 3.00 3.00 5.00 5.00

PROCEPT BioRobotics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 6.00 6.00 5.00 4.00

PRCT vs ENOV, INSP, IRMD: Piotroski F-Score Comparison

For the Medical Devices subindustry, PROCEPT BioRobotics's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PROCEPT BioRobotics Piotroski F-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, PROCEPT BioRobotics's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where PROCEPT BioRobotics's Piotroski F-Score falls into.


PRCT
70GF Score
PROCEPT BioRobotics Corp PRCT
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -19.578 + -21.411 + -29.845 + -31.638 = $-102.5 Mil.
Cash Flow from Operations was -15.043 + -6.635 + -10.327 + -38.127 = $-70.1 Mil.
Revenue was 79.182 + 83.327 + 76.383 + 83.132 = $322.0 Mil.
Gross Profit was 51.746 + 54.006 + 46.313 + 53.947 = $206.0 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(519.375 + 513.054 + 511.541 + 508.081 + 487.062) / 5 = $507.8226 Mil.
Total Assets at the begining of this year (Mar25) was $519.4 Mil.
Long-Term Debt & Capital Lease Obligation was $75.6 Mil.
Total Current Assets was $428.0 Mil.
Total Current Liabilities was $63.6 Mil.
Net Income was -25.626 + -20.974 + -18.856 + -24.737 = $-90.2 Mil.

Revenue was 53.353 + 58.37 + 68.236 + 69.162 = $249.1 Mil.
Gross Profit was 31.482 + 36.911 + 43.672 + 44.161 = $156.2 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(382.9 + 374.35 + 374.142 + 534.017 + 519.375) / 5 = $436.9568 Mil.
Total Assets at the begining of last year (Mar24) was $382.9 Mil.
Long-Term Debt & Capital Lease Obligation was $77.8 Mil.
Total Current Assets was $465.8 Mil.
Total Current Liabilities was $52.1 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

PROCEPT BioRobotics's current Net Income (TTM) was -102.5. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

PROCEPT BioRobotics's current Cash Flow from Operations (TTM) was -70.1. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-102.472/519.375
=-0.19729868

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-90.193/382.9
=-0.23555236

PROCEPT BioRobotics's return on assets of this year was -0.19729868. PROCEPT BioRobotics's return on assets of last year was -0.23555236. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

PROCEPT BioRobotics's current Net Income (TTM) was -102.5. PROCEPT BioRobotics's current Cash Flow from Operations (TTM) was -70.1. ==> -70.1 > -102.5 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=75.638/507.8226
=0.14894571

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=77.83/436.9568
=0.17811829

PROCEPT BioRobotics's gearing of this year was 0.14894571. PROCEPT BioRobotics's gearing of last year was 0.17811829. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=428.034/63.636
=6.72628701

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=465.791/52.064
=8.94650814

PROCEPT BioRobotics's current ratio of this year was 6.72628701. PROCEPT BioRobotics's current ratio of last year was 8.94650814. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

PROCEPT BioRobotics's number of shares in issue this year was 56.511. PROCEPT BioRobotics's number of shares in issue last year was 54.917. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=206.012/322.024
=0.63974114

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=156.226/249.121
=0.62710891

PROCEPT BioRobotics's gross margin of this year was 0.63974114. PROCEPT BioRobotics's gross margin of last year was 0.62710891. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=322.024/519.375
=0.62002214

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=249.121/382.9
=0.65061635

PROCEPT BioRobotics's asset turnover of this year was 0.62002214. PROCEPT BioRobotics's asset turnover of last year was 0.65061635. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+0+0+1+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

PROCEPT BioRobotics has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
PROCEPT BioRobotics (PRCT) has a Piotroski F-Score of 4 as of Jun. 29, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on PROCEPT BioRobotics and its competitors. This is 20% below median its historical median of 5.00. Over the past decade, PROCEPT BioRobotics' Piotroski F-Score has ranged from 2.00 to 6.00. According to the industry distribution chart, PROCEPT BioRobotics ranks #455 out of 806 companies in the Medical Devices & Instruments industry, placing it in the top 56.5%.
Is PROCEPT BioRobotics' Piotroski F-Score too high?
PROCEPT BioRobotics' current Piotroski F-Score of 4 is 20% below median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 6.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. PROCEPT BioRobotics' value of 4 is 20% below this industry median. Based on the distribution chart, PROCEPT BioRobotics ranks #455 out of 806 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, PROCEPT BioRobotics has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PROCEPT BioRobotics' Piotroski F-Score compare to ENOV and INSP?
According to the Medical Devices & Instruments industry distribution chart, PROCEPT BioRobotics ranks #455 out of 806 companies for Piotroski F-Score. This places PROCEPT BioRobotics in the lower half of its industry. The industry median Piotroski F-Score is 5.00. PROCEPT BioRobotics' value of 4 is 20% below this benchmark. Historically, PROCEPT BioRobotics' own Piotroski F-Score has ranged from 2.00 to 6.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, PROCEPT BioRobotics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 806 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PROCEPT BioRobotics's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on PROCEPT BioRobotics and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PROCEPT BioRobotics's current Piotroski F-Score is 4, which is 20% below median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROCEPT BioRobotics stock overvalued right now?
Based on GuruFocus' analysis, PROCEPT BioRobotics (PRCT) is currently considered Significantly Undervalued. The stock's GF Value™ is $92.12, compared to a current price of $22.65 — trading 75.4% below its estimated fair value. The current Piotroski F-Score is 4, which is 20% below median its 10-year median of 5.00 and 20% below the Medical Devices & Instruments industry median of 5.00. PROCEPT BioRobotics' overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For PROCEPT BioRobotics (PRCT), the current Piotroski F-Score is 4 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PROCEPT BioRobotics (PRCT) Overvalued in 2026?

Based on GuruFocus' analysis, PROCEPT BioRobotics stock appears to be undervalued. The current stock price of $22.65 is trading 75.4% below its estimated GF Value™ of $92.12. GuruFocus considers PROCEPT BioRobotics to be Significantly Undervalued.

Key valuation signals for PRCT:

  • Piotroski F-Score: 4 (20% below median its 10-year median of 5.00)
  • GF Value™: $92.12 vs. price of $22.65 (75.4% below fair value)
  • GF Score™: 70/100 with 2 warning signs
  • Industry Position: 20% below the Medical Devices & Instruments median (#455 of 806)

No single metric tells the full story. See the PRCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PROCEPT BioRobotics Business Description

Other Exchanges PRCT:Mexico
Address 150 Baytech Drive, San Jose, CA, USA, 95134
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
70GF Score

Get the complete analysis for PRCT

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.65
Price
$92.12
GF Value